Table 1.
model | species | effective doses | CBD effect | references |
---|---|---|---|---|
studies with laboratory animals | ||||
Geller-Seifter conflict model | rat | 100 mg kg−1 i.p. | no effect | [5] |
conditioned emotional responses | rat | 10 mg kg−1 i.p. | ↓ | [6] |
EPM | rat | 2.5–10 mg kg−1 i.p | ↓ | [7] |
EPM | mouse | 1–10 mg kg−1 i.p. | ↓ | [8] |
VCT | rat | 10 mg kg−1 | ↓ | [9] |
CFC | rat | 10 mg kg−1 i.p. | ↓; decreased autonomic responses | [10] |
predator exposure (Cat)+ EPM | rat | 5 mg kg−1 | ↓ | [11] |
restraint stress + EPM | rat | 30 nmol intra-cisterna magna | decreased autonomic and delayed anxiogenic effect | [12] |
predator exposure (snake) | mouse | 3–30 mg kg−1 i.p. | panicolytic | [13] |
marble burying | mouse | 30 mg kg−1 i.p | decreased compulsive behaviour | [14] |
CFC/fear memory extinction | rat | 6.35 nmol i.c.v. | ↓; facilitated extinction | [15] |
ETM/DPAG electric stimulation | rat | 30–60 nmol intra-DPAG | ↓, panicolytic | [16] |
restraint stress + EPM | rat | 10 mg kg−1 i.p. | decreased autonomic and delayed anxiogenic effect | [17] |
EPM/VCT | rat | 15–30 nmol intra-DPAG | ↓ | [18] |
EPM/VCT | rat | 30–60 nmol intra-BNST | ↓ | [19] |
CFC | rat | 30–60 nmol intra-BNST | ↓, decreased autonomic responses | [20] |
CFC | rat | 30 nmol intra-PL | ↓ | [21] |
CFC | rat | 30 nmol intra-IL | ↑ | [21] |
CFC | rat | 10 mg kg−1 i.p./daily/14 days | ↑ | [22] |
CFC/fear reconsolidation | rat | 10 mg kg−1 i.p. | ↓; memory reconsolidation impairment | [23] |
model/measures | subjects | dose (mg, p.o.) | CBD effect | references |
clinical studies | ||||
simulated public-speaking | healthy volunteers | 400 mg | ↓ | [24] |
neuroimaging study | healthy volunteers | 400 mg | ↓ | [25] |
fearful facial stimuli | healthy volunteers | 600 mg | ↓ | [26] |
fearful facial stimuli | healthy volunteers | 600 mg | ↓ | [27] |
anxiety symptoms (visual analogue mood scale) | GAD | 400 mg | ↓ | [28] |
simulated public speaking | social phobics | 400 mg | ↓ | [29] |